Company
2 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of manufacturing changes for Wegovy; no clinical efficacy or safety data are reported in this regulatory action.
JUN 2, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for labeling change to liraglutide (Saxenda); describes regulatory action only, not clinical trial evidence or efficacy data.